Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$FWDG "Cannabidiol (CBD) nutritional supplement" NEWS..."ALERT" Futureworld FWDG "HempTECH" announces HempTechRX. (subsystem) . http://finance.yahoo.com/news/futureworld-fwdg-hemptech-create-hemptechrx-120200161.html
SAEI - still waiting for Supatcha to produce tangible evidence proving any of their claims of Gold deposits and offers to buy-out their stock. As for right now they are on the grey market after having trading suspended by the SEc. That alone speaks volumes.
Post Unavailable
Paid members have full access to advanced search options allowing them to find and view other members posts on all boards. This function is quite usefull when reviewing what someone posted about stocks they intended to buy, bought and sold. This allows someone to also check the stock price at the time of the posts by checking that stocks price chart for that day. It will help you clearly see if that person actually made money based on when they posted there buys and sells.
I spell this out clearly just in case someone wants to go back and check my posts in any stock I "claimed" to buy and sell. I have been very clear for the specific reason that I want no one ot buy a stock I'm in or singing the praises of unless I'm either in it or about to get in it. And then they can also know when I felt it best to get out. I think that kind of transparency is crucial on a board, like ihub, that could someone use to lead people into investments just to unload their own shares.
In this light my posting history speaks for itself. And so does the posting history of everyone else.
When considering taking anyone's trading advice here in ihub at least search that persons other post's and see if they are transparent about their own trading activities as they are making trades. If they are not then follow them at your own risk.
Very, very interesting.
HEB - short interest is more than insider holdings,...
creates a puzzling hypothesis.
could management be hedging ? or is it an outside (informed) influence
Hemispherx Biopharma Inc $ 2.42
HEB -0.12
Short Interest (Shares Short) 10,269,000
Days To Cover (Short Interest Ratio) 0.5
Short Percent of Float 12.39 %
Short Interest - Prior 7,046,100
Short % Increase / Decrease 45.74 %
Short Squeeze Ranking™ 13
% From 52-Wk High ($ 4.54 ) -78.74 %
% From 52-Wk Low ($ 0.25 ) 90.16 %
% From 200-Day MA ($ 0.89 ) 64.96 %
% From 50-Day MA ($ 2.10 ) 17.32 %
Price % Change (52-Week) 217.50 %
Shares Float 82,860,000
Total Shares Outstanding 84,621,416
% Owned by Insiders 7.82 %
% Owned by Institutions 2.40 %
HEB,...short interest increases,...
the question is why ?
if there is such positive sentiment of an FDA approval for their Ampligen treatment for CFS why the increased short interest ? who knows something and are they preparing for it ?
i don't have the answer just posing the inquiry.
June 19, 2009 8:24:42 AM
Hemispherx Biopharma Inc $ 2.45
Short Interest (Shares Short) 7,046,100
Days To Cover (Short Interest Ratio) 0.5
Short Percent of Float 8.50 %
Short Interest - Prior 4,990,800
Short % Increase / Decrease 41.18 %
Short Squeeze Ranking™ 10
and now,...
June 30, 2009
Hemispherx Biopharma Inc $ 2.54
Short Interest (Shares Short) 10,269,000
Days To Cover (Short Interest Ratio) 0.5
Short Percent of Float 12.39 %
Short Interest - Prior 7,046,100
Short % Increase / Decrease 45.74 %
Short Squeeze Ranking™ 14
Thanks. I'm sure this will be helpful information for shareholders or potential shareholders to use when making their trading decisions.
i really haven't formed an opinion yet as i'm still reviewing the story about DNDN. but i see a pattern that *could* emerge with this stock.
part of what i don't like is the HEB forum moderators choose to delete this information and called it Off Topic. that is slanted and it brings suspicion to the forum and its sense of complete due diligence.
i think a few items to keep in view are 1- the short position now in place and if the short position increases and by what percentage; 2- if articles begin to be addressed that are negative regarding FDA approval,..that is unproportionate amount of articles that are in conflict with what the BOD of this company is stating; 3 - insider buys and sells.
to keep track of those concerns,...
Short Position
(per Yahoo!Finance)
Shares Outstanding: 84.62M
Float: 82.05M
% Held by Insiders1: 7.82%
% Held by Institutions1: 2.40%
Shares Short (as of 10-Jun-09)3: 10.27M
Short Ratio (as of 10-Jun-09)3: 0.5
Short % of Float (as of 10-Jun-09)3: 12.50%
Shares Short (prior month)3: 7.05M
Insider Cow
(just type in company ticker)
http://www.insidercow.com/
Interesting Read. Thanks for sharing this information. Do you think that their are other factors impacting the share price here. Do you have an opinion on why this stock price may being driven down on "mistaken" bad news when the verdict is still not out?
NoTiCe,..
my purpose to post this information is solely for adding to the due diligence of this company, HEB. and to bring to any and all HEB investors complete infomration that is out for all to discern.
the moderators at the HEB iHub forum choose to delete this information. by deleting this information they are taking the position that they will not allow the forum to read this information which might assist investors a better understanding of what 'might' be in the cards for HEB. not that it will occur but with information of a pattern in this market sector DNDN is in it might spillover to HEB.
why would the moderators remove possible crucial information that investors in HEB would want to know ? i don't have that answer,...but it's not a fair playing field that is being created at the HEB iHub forum if they are choosing to delete information that is in fact on topic and in fact educates the HEB investor what to look out for. at least allow the forum participants to read this and bring discussion. they have the right to have all information that could have potential influence on the share price. you, as moderator(s), do not have the right to remove what will soon be on the next page and expose investors to potential loss.
as much as everyone would like to believe this type of action couldn't happen to HEB,..it in fact can occur with HEB.
here is what was deleted,...
yes,..it could be the next DNDN (share price moves high parabolically),...and not STRICTLY in the positive sense (shorts drive share price down parabolically),...which is why you, if you are a shareholder in HEB, need to read this;
Michael Milken, 60,000 Deaths, and the Story of Dendreon (Chapter 1 of 15)
http://www.deepcapture.com/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
What follows is part 1 of a 15-part series. The remaining installments will appear on Deep Capture over the next several weeks, after which point the story will be published in its entirety. It is a story about the travails of just one small company, but it describes market machinations that have affected hundreds of other companies, and it contains a larger message for anyone concerned about the “deep capture” of our nation’s media and regulatory bodies.
* * * * * * * *
This story, like too many others, begins with Jim Cramer, the CNBC personality, making “a mistake.”
On September 26, 2005, Cramer announced to his television audience the sad news (punctuated by funny sound effects – a clown horn, a crashing airplane) that Provenge, an experimental treatment for prostate cancer, had flopped. Thousands of end-stage patients had been pinning their hopes on Provenge, but according to Cramer the treatment had just been rejected by the Food & Drug Administration. It would never go to market.
This seemed odd, because Dendreon (NASDAQ: DNDN), the company developing Provenge, had not yet submitted an application for FDA approval. As everybody in the biotech investment community knew, Dendreon had, in fact, only recently completed Phase 3 clinical trials and probably would not face scrutiny from an FDA advisory panel for at least another year.
As for the likelihood that the advisory panel would eventually vote in favor of Provenge, the odds looked quite good. The Phase 3 trials had demonstrated that Provenge significantly increased patient survival with only minimal side-effects, such as a few days of mild fever. Moreover, Provenge was an altogether different sort of treatment – one that fought tumors by boosting patients’ immune systems rather than subjecting them to the ravages of chemotherapy.
Provenge was not a magical elixir of life, but Dendreon was doing more than just developing a new technology. It was pioneering a treatment that could revolutionize the way that doctors fight prostate cancer. By some conservative estimates, the market for Provenge alone could reach more than $2 billion a year. If the treatment could be applied to other cancers, the market would be even larger.
The morning after Cramer declared Dendreon and Provenge to be dead in the water, Mark Haines, the anchor of CNBC’s “Squawk Box” program, apologized for Cramer’s “mistake.” That afternoon, at an important UBS investor conference, Dendreon presented still more promising data. This would normally have given a significant boost to the company’s stock price, but the value of Dendreon’s shares stayed flat for the day, and then began a gradual decline.
This had partly to do with Cramer. The next evening, on his “Mad Money” program, the journalist (or entertainer, or self-confessed criminal, or… whatever Cramer is) acknowledged that the FDA had not yet rejected Provenge, but drawing upon his medical expertise, Cramer maintained that Provenge was not effective. In characteristically level-headed fashion, he announced that Dendreon shareholders were drunken, carousing, gambling Falstaffs who “might as well take their money to Vegas.”
Dendreon, Cramer added (rather ominously), was a “battleground stock.”
story continues. chapter 2,3 & 4 are posted also. http://www.deepcapture.com/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
WELCOME to the 'Is THIS Stock Safe?' Board!!!
This board is here simply to provide wary investors a place to pose that very question and get answers/opinions from:
(1) Those who are educated about the particular stock in question
(2) Those who have had experience with the stock or company
(3) Those with pertinent information about the stock or company
or
(4) Those who wish to share information about other stocks trading patterns that are similar to the stock in question.
NO STOCK is 100% "Safe" or guaranteed to give you a return on your investment. However you can still determine whether a stock is "Safe" for you by evaluating the level of risk a stock has, based on the available information on that stock. By properly considering the risk you can decrease your potential losses. If you decide to trade a stock after evaluating the risk you will then be more aware of things to look for that could signal the time to sell that stock.
ALL opinion's are welcome as long as they are civil. Please make every attempt to support your opinion as clearly as possible to help other traders/investors gain as much information and make clearly trading decisions.
Although this board may contain some DD for some stocks this is NOT to be considered anyone's main source for trading information. Instead, at best it should supplement other deeper stock, company and trading research.
Finally, in sharing your opinions, humor is fully welcome here. Lively, vibrant and feisty debate is welcome but it must be done in a humble way that recognizes that no matter how much someone knows NO-ONE has all the right answers.
Enjoy!!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |